XRP Extends Monthly Slide to 26%, Testing Critical Support Levels
XRP has retreated 25.5% over the past month to trade near $1, as analysts warn of potential further declines toward the $0.60 to $0.90 range if key support fails.
📈MarketsPhoto: Benzinga
Key points
- XRP dropped 25.5% over the past month, trading near the $1 mark after failing to break $1.55 resistance.
- Analysts warn that a failure to hold the $0.99 support could trigger a slide toward $0.80 or the $0.60–$0.90 accumulation zone.
- Former Ripple CTO David Schwartz reduced his XRP holdings by 88% amid concerns over investment risk.
The digital asset XRP has recorded a steep monthly pullback of 25.5%, recently slipping to the $1 threshold following a sharp rejection at the $1.55 resistance ceiling. Crypto chart analyst Ali Martinez noted that the token has retreated toward the lower boundary of its established trading channel, emphasizing that the $0.99 price point must hold to prevent a deeper correction toward $0.80.
Market observers suggest that ongoing weakness could drive prices even lower before any substantial recovery materializes. Independent trader CrediBULL Crypto indicated that the cryptocurrency might slide past $0.98 to enter an accumulation zone between $0.60 and $0.90. While a deeper pullback could pave the way for a more durable upward move later, current market momentum points toward continued near-term pressure.
Adding to the cautious sentiment, Ripple's former chief technology officer, David Schwartz, significantly trimmed his personal crypto portfolio. Schwartz reduced his XRP holdings by 88%—dropping from 26 million tokens to approximately 3 million—while also scaling back his Bitcoin and Ethereum positions due to a reduced tolerance for investment risk.
What to watch next: Investors should monitor whether the $0.99 support level holds against ongoing selling pressure or if the asset breaks lower toward the anticipated $0.60–$0.90 accumulation range.
Source Benzinga — benzinga.com/crypto/cryptocurrency/26/11/63237302/xrp-drops-26-in-a… ↗
Read next
🧠AI AnalysisPfizer Discontinues Premarin Hormone Therapy in Canada Following Internal Review
Pfizer is ending sales of its Premarin menopause hormone therapy in Canada, impacting both vaginal cream and oral tablets while hospital treatments remain unaffected.
🧠AI AnalysisNvidia Prepares for Historic Earnings Call as Colette Kress Steps in for Jensen Huang
Nvidia faces a major leadership transition on November 17 as interim CEO Colette Kress leads her first quarterly earnings call without founder Jensen Huang after 33 years…
🧠AI AnalysisTikTok Parent ByteDance Reaches $400 Billion Valuation, Overshadowing Partner Oracle
ByteDance's latest $6 billion share buyback values the TikTok parent at $400 billion, surpassing Oracle's $384 billion market capitalization and intensifying competitive …
💳Personal FinanceCrown Crafts Reports Lower Sales in Q2 Fiscal 2027, Citing Margin Gains and Debt Reduction
Consumer goods company Crown Crafts posted a drop in quarterly revenue due to tough year-over-year comparisons, but managed to expand profit margins and cut long-term deb…
💳Personal FinanceThe Evolving Nature of Quality Stocks in Modern Portfolios
Market analysts examine how the definition and characteristics of quality equity factors are shifting for everyday investors.
🌍World BusinessUnipol Navigates Q3 Headwinds from Northern Italy Natural Catastrophes and Bond Spreads
Unipol Assicurazioni reported a solid third quarter for 2026 despite facing natural catastrophe impacts in Northern Italy and widening government bond spreads that pressu…